Charles Schwab Investment Management Inc. Has $266.72 Million Stock Holdings in Humana Inc. $HUM

Charles Schwab Investment Management Inc. raised its position in Humana Inc. (NYSE:HUM) by 4.3% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 1,090,978 shares of the insurance provider’s stock after acquiring an additional 45,129 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Humana were worth $266,722,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Cary Street Partners Investment Advisory LLC lifted its holdings in shares of Humana by 63.9% in the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider’s stock worth $31,000 after purchasing an additional 46 shares in the last quarter. Blue Trust Inc. raised its holdings in Humana by 3.6% during the second quarter. Blue Trust Inc. now owns 1,367 shares of the insurance provider’s stock worth $334,000 after buying an additional 48 shares during the last quarter. Atlas Brown Inc. lifted its stake in shares of Humana by 0.9% in the second quarter. Atlas Brown Inc. now owns 6,369 shares of the insurance provider’s stock valued at $1,557,000 after buying an additional 54 shares in the last quarter. Townsquare Capital LLC grew its holdings in shares of Humana by 2.8% during the first quarter. Townsquare Capital LLC now owns 2,255 shares of the insurance provider’s stock valued at $597,000 after buying an additional 61 shares during the last quarter. Finally, Sound View Wealth Advisors Group LLC grew its holdings in shares of Humana by 5.8% during the first quarter. Sound View Wealth Advisors Group LLC now owns 1,154 shares of the insurance provider’s stock valued at $305,000 after buying an additional 63 shares during the last quarter. Institutional investors own 92.38% of the company’s stock.

Humana Trading Up 1.1%

NYSE HUM opened at $229.67 on Tuesday. The business’s fifty day moving average is $264.87 and its 200-day moving average is $256.94. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.95 and a quick ratio of 1.95. The stock has a market capitalization of $27.62 billion, a price-to-earnings ratio of 17.63, a PEG ratio of 1.71 and a beta of 0.42. Humana Inc. has a one year low of $206.87 and a one year high of $315.35.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, November 5th. The insurance provider reported $3.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.95 by $0.29. The business had revenue of $32.65 billion during the quarter, compared to the consensus estimate of $31.99 billion. Humana had a net margin of 1.28% and a return on equity of 13.67%. The firm’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same quarter last year, the company posted $4.16 earnings per share. Equities research analysts predict that Humana Inc. will post 16.47 EPS for the current year.

Humana Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Friday, December 26th will be paid a $0.885 dividend. The ex-dividend date is Friday, December 26th. This represents a $3.54 annualized dividend and a yield of 1.5%. Humana’s dividend payout ratio is presently 33.18%.

Wall Street Analyst Weigh In

HUM has been the topic of several recent research reports. Evercore ISI assumed coverage on shares of Humana in a research report on Monday, September 22nd. They issued an “in-line” rating and a $295.00 price target on the stock. Piper Sandler dropped their target price on Humana from $288.00 to $272.00 and set a “neutral” rating on the stock in a report on Thursday, July 31st. Wall Street Zen cut Humana from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. The Goldman Sachs Group assumed coverage on Humana in a research report on Tuesday, October 14th. They issued a “sell” rating and a $235.00 price target for the company. Finally, Wolfe Research dropped their price objective on Humana from $313.00 to $300.00 and set an “outperform” rating on the stock in a research note on Thursday, November 20th. Eight investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $297.67.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.